Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 98Stomach Neoplasms 50Rectal Neoplasms 45Pancreatic Neoplasms 45Colonic Neoplasms 36Esophageal Neoplasms 34Neoplasms 30Neoplasm Metastasis 28Squamous Cell Carcinoma of Head and Neck 27Head and Neck Neoplasms 24Breast Neoplasms 21Adenocarcinoma Of Esophagus 20Parkinson Disease 4, Autosomal Dominant Lewy Body 12Adenocarcinoma 9Anus Neoplasms 8Esophageal Squamous Cell Carcinoma 7Carcinoma, Squamous Cell 7Carcinoma 7Cholangiocarcinoma 6Liver Neoplasms 5Gallbladder Neoplasms 5Bile Duct Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Adenocarcinoma 4Gastrointestinal Neoplasms 4Carcinoma, Hepatocellular 4Skin Neoplasms 3Sarcoma 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3

Interventions

Temozolomide 3Capecitabine 3Everolimus 2Bevacizumab 2regorafenib 1motesanib diphosphate 1batifiban 1Sorafenib 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrinoma × Fluorouracil × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡